Key Stats for Roivant Sciences Stock
- Price Change: +17.9%
- Current Price: ~$26
- Street High Target: $33
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Roivant Sciences (ROIV) skyrocketed 17.9% to close near $25.82 on Friday, hitting a new 52-week high after releasing “transformational” data from a mid-stage clinical trial.
The catalyst was the announcement of positive Phase 2 results for brepocitinib in patients with cutaneous sarcoidosis, a rare inflammatory skin disease with no FDA-approved therapies.
Investors aggressively bid up the stock after the drug demonstrated a “statistically significant” benefit.
100% of patients in the high-dose arm achieved a clinically meaningful response compared to just 14% on placebo.
The study data were overwhelming: the drug achieved a placebo-adjusted improvement of 21.6 points on the severity index, far exceeding the 5-point bar for clinical success.
Furthermore, 62% of patients on the high dose achieved functional remission, compared to 0% of patients on placebo.
This clinical triumph completely overshadowed a mixed fiscal Q3 earnings report
The company missed revenue estimates ($2.0 million vs. $5.1 million expected) but maintained a fortress balance sheet with $4.5 billion in cash.
Analysts at Goldman Sachs and Leerink Partners have maintained bullish ratings with price targets in the $32-$33 range.
They argued that the market is underappreciating the commercial potential of Roivant’s “pipeline in a product” strategy.
The sentiment on Wall Street has shifted decisively, with the “Street High” target now sitting at $33, suggesting that the breakout has further to run as the company advances toward a pivotal Phase 3 trial later this year.
See analysts’ growth forecasts and price targets for Roivant Sciences stock (It’s free!) >>>
Is Roivant Sciences Undervalued Today?
During the earnings call, CEO Matt Gline expressed enthusiasm about the trial success, stating that the drug “has done everything we could have asked for… in this study.”
He highlighted the specific data points driving the stock’s rally: “We got a placebo-adjusted almost 22 points… [and] 100% of patients on brepo 45… had a 10-point improvement.”
Priovant CEO Ben Zimmer reinforced the strength of the signal, adding: “The effect sizes we see here are extremely large… we see them very consistently across multiple different endpoints… including the 100% response rate for the brepo 45-milligram arm.”
Looking ahead, Gline confirmed the company is fully funded to execute on these opportunities: “Cash remains very strong, $4.5 billion of consolidated cash… plenty of capital to get us to profitability.”
Read the full Roivant Transcript on TIKR to see the 2026 Roadmap >>>
The TIKR Street Consensus paints a clear picture of the upside potential.
- Street High Target: $33
- Current Price: ~$26
- Potential Upside: +27.8%
Valuation Deep Dive
The investment case for Roivant is a “Sum-of-the-Parts” thesis, where the value of its cash and individual drug assets exceeds the current market cap.
With the stock trading at ~$26, investors are effectively getting the pipeline for free, given the massive cash pile, but the $33 target price is successful for key assets like brepocitinib.
- The Clinical De-Risking: The Phase 2 win for brepocitinib adds a new “shot on goal” to the valuation, increasing the probability of approval in a market with zero competition.
- The Cash Floor: With $4.5 billion in cash, Roivant has a massive safety net that prevents dilution and allows for opportunistic M&A or share buybacks.
- The Value Gap: The $33 target reflects the Street’s belief that Roivant’s diverse portfolio of “Vants” will continue to monetize assets at premium valuations, similar to the Roche-Telavant deal.
If Roivant can replicate this clinical success in its other late-stage trials, the re-rating to $33 could happen rapidly as institutional investors chase the growth.
Conclusion: A breakout year. With a 27.8% upside potential to $33, Roivant Sciences offers a compelling mix of clinical upside and balance sheet safety for biotech investors looking to ride the momentum of a major pipeline win.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
How Much Upside Does Roivant Sciences Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
